Ahmad N, Kuramoto I K, Baroudy B M
Division of Molecular Virology, James N. Gamble Institute of Medical Research, Cincinnati, OH 45219, USA.
Clin Diagn Virol. 1993 Oct;1(4):233-44. doi: 10.1016/0928-0197(93)90005-p.
A ribonuclease protection assay (RPA) was developed for the direct detection and quantitation of HCV RNA in infected patients' sera or plasma using HCV [(32)P]RNA from the conserved 5'-untranslated region (5'-UTR) as a probe. We were able to directly detect the presence of HCV RNA by RPA in several infected patients' samples. The viremic status of HCV infected patients with indeterminate recombinant immunoblot assay (RIBA II) was also determined by this assay. Polymerase chain reaction (PCR) was also performed on all these samples and were found to be positive with a concordance of 100% between the results of PCR and RPA. The RPA was able to detect approximately 1 pg of HCV RNA. A limited sequence heterogeneity among HCV isolates was also observed by this assay, suggesting that this may be a faster method of detecting heterogeneous HCV sequences in patients' samples. This simple and specific method could be used to quantitate HCV RNA in order to better determine viremia and follow the course of HCV infection especially when RIBA II results are indeterminate.
开发了一种核糖核酸酶保护分析(RPA),用于使用来自保守5'-非翻译区(5'-UTR)的丙型肝炎病毒(HCV)[(32)P]RNA作为探针,直接检测和定量感染患者血清或血浆中的HCV RNA。我们能够通过RPA在几个感染患者的样本中直接检测到HCV RNA的存在。该分析还确定了重组免疫印迹分析(RIBA II)结果不确定的HCV感染患者的病毒血症状态。对所有这些样本也进行了聚合酶链反应(PCR),发现结果均为阳性,PCR和RPA结果之间的一致性为100%。RPA能够检测到约1 pg的HCV RNA。通过该分析还观察到HCV分离株之间存在有限的序列异质性,这表明这可能是一种在患者样本中检测异质性HCV序列的更快方法。这种简单而特异的方法可用于定量HCV RNA,以便更好地确定病毒血症并跟踪HCV感染的进程,特别是当RIBA II结果不确定时。